Literature DB >> 23630965

Rho kinase regulates induction of T-cell immune dysfunction in abdominal sepsis.

Z Hasan1, K Palani, S Zhang, M Lepsenyi, R Hwaiz, M Rahman, I Syk, B Jeppsson, Henrik Thorlacius.   

Abstract

T-cell dysfunction increases susceptibility to infections in patients with sepsis. In the present study, we hypothesized that Rho kinase signaling might regulate induction of T-cell dysfunction in abdominal sepsis. Male C57BL/6 mice were treated with the specific Rho kinase inhibitor Y-27632 (5 mg/kg of body weight) prior to cecal ligation and puncture (CLP). Spleen CD4 T-cell apoptosis, proliferation, and percentage of regulatory T cells (CD4(+) CD25(+) Foxp3(+)) were determined by flow cytometry. Formation of gamma interferon (IFN-γ) and interleukin 4 (IL-4) in the spleen and plasma levels of HMBG1, IL-17, and IL-6 were quantified by use of enzyme-linked immunosorbent assay (ELISA). It was found that CLP evoked apoptosis and decreased proliferation in splenic CD4 T cells. Inhibition of Rho kinase activity decreased apoptosis and enhanced proliferation of CD4 T cells in septic animals. In addition, CLP-evoked induction of regulatory T cells in the spleen was abolished by Rho kinase inhibition. CLP reduced the levels of IFN-γ and IL-4 in the spleen. Pretreatment with Y-27632 inhibited the sepsis-induced decrease in IFN-γ but not IL-4 formation in the spleen. CLP increased plasma levels of high-mobility group box 1 (HMGB1) by 20-fold and IL-6 by 19-fold. Inhibition of Rho kinase decreased this CLP-evoked increase of HMGB1, IL-6, and IL-17 levels in the plasma by more than 60%, suggesting that Rho kinase regulates systemic inflammation in sepsis. Moreover, we observed that pretreatment with Y-27632 abolished CLP-induced bacteremia. Together, our novel findings indicate that Rho kinase is a powerful regulator of T-cell immune dysfunction in abdominal sepsis. Thus, targeting Rho kinase signaling might be a useful strategy to improve T-cell immunity in patients with abdominal sepsis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23630965      PMCID: PMC3697588          DOI: 10.1128/IAI.00126-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis.

Authors:  Shigeto Oda; Hiroyuki Hirasawa; Hidetoshi Shiga; Kazuya Nakanishi; Ken-ichi Matsuda; Masataka Nakamua
Journal:  Cytokine       Date:  2004-12-08       Impact factor: 3.861

Review 3.  Rho kinases in cardiovascular physiology and pathophysiology.

Authors:  Gervaise Loirand; Patrice Guérin; Pierre Pacaud
Journal:  Circ Res       Date:  2006-02-17       Impact factor: 17.367

4.  Induction of proinflammatory mediators requires activation of the TRAF, NIK, IKK and NF-kappaB signal transduction pathway in astrocytes infected with Escherichia coli.

Authors:  J M Kim; Y-K Oh; J H Lee; D Y Im; Y-J Kim; J Youn; C-H Lee; H Son; Y-S Lee; J Y Park; I-H Choi
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

5.  Fasudil, a Rho-kinase inhibitor, inhibits leukocyte adhesion in inflamed large blood vessels in vivo.

Authors:  J E Slotta; O O Braun; M D Menger; H Thorlacius
Journal:  Inflamm Res       Date:  2006-09       Impact factor: 4.575

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis.

Authors:  Guillaume Monneret; Anne-Lise Debard; Fabienne Venet; Julien Bohe; Olivier Hequet; Jacques Bienvenu; Alain Lepape
Journal:  Crit Care Med       Date:  2003-07       Impact factor: 7.598

Review 8.  Molecular mechanisms of endotoxin tolerance.

Authors:  Hongkuan Fan; James A Cook
Journal:  J Endotoxin Res       Date:  2004

Review 9.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 10.  Extracellular role of HMGB1 in inflammation and sepsis.

Authors:  H Wang; H Yang; K J Tracey
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989

View more
  8 in total

1.  Levosimendan for Septic Myocardial Dysfunction: Not Yet Ready for Prime Time.

Authors:  Diana Pang; Rajesh K Aneja
Journal:  Crit Care Med       Date:  2015-11       Impact factor: 7.598

Review 2.  Modulation of microenvironment for controlling the fate of periodontal ligament cells: the role of Rho/ROCK signaling and cytoskeletal dynamics.

Authors:  Tadashi Yamamoto; Yuki Ugawa; Mari Kawamura; Keisuke Yamashiro; Shinsuke Kochi; Hidetaka Ideguchi; Shogo Takashiba
Journal:  J Cell Commun Signal       Date:  2017-10-30       Impact factor: 5.782

3.  Protective effect of pantoprazole against sepsis-induced acute lung and kidney injury in rats.

Authors:  Xi-Xiang Yan; Ai-Dong Zheng; Zhen-En Zhang; Guo-Cui Pan; Wen Zhou
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

4.  Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.

Authors:  Brian Yu; Nikola Sladojevic; John E Blair; James K Liao
Journal:  Expert Opin Ther Targets       Date:  2020-01-09       Impact factor: 6.902

Review 5.  The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases.

Authors:  Yun Ge; Man Huang; Yong-Ming Yao
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

Review 6.  Complement After Trauma: Suturing Innate and Adaptive Immunity.

Authors:  Shinjini Chakraborty; Ebru Karasu; Markus Huber-Lang
Journal:  Front Immunol       Date:  2018-09-24       Impact factor: 7.561

Review 7.  Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential.

Authors:  Seohyun Kim; Seong A Kim; Jihoon Han; In-San Kim
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

Review 8.  Histone Deacetylation Inhibitors as Modulators of Regulatory T Cells.

Authors:  Andreas von Knethen; Ulrike Heinicke; Andreas Weigert; Kai Zacharowski; Bernhard Brüne
Journal:  Int J Mol Sci       Date:  2020-03-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.